Zion Market Research has published a new report titled “Irritable Bowel Syndrome Treatment Market by Product (Constella/Linzess, Amitiza, Xifaxan, Viberzi, and Others) and Product (IBS-D and IBS-C): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025” According to the report, global demand for irritable bowel syndrome treatment market was valued at approximately USD 1,562.4 Million in 2018, and is expected to generate revenue of around USD 3,085.0 Million by end of 2025, growing at a CAGR of around 10.3% between 2019 and 2025.
Irritable Bowel Syndrome (IBS) is an ailment that interrupts the large intestine. The indications of IBS include cramping, abdominal pain, gas, bloating, and diarrhea. The management of IBS is a long duration process. Mild symptoms can be controlled by handling lifestyle, diet, and stress. However, severe symptoms require counseling and medication. IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C) are two major types of IBS.
Request For Free Sample Report @ https://www.zionmarketresearch.com/sample/irritable-bowel-syndrome-treatment-market
Factors such as increasing prevalence of IBS, growing use of medication for the treatment of IBS, increasing commercialization of available drugs in multiple regions, and increasing trend of unhealthy lifestyle will act as major driving factors in the growth of global irritable bowel syndrome treatment market. Launch of new products and investment in research and development will act as an opportunity for the market players in the irritable bowel syndrome treatment market. Nonetheless, lack of awareness and dearth of skilled physicians in low-income countries will restrict the growth of global irritable bowel syndrome treatment market.
The global irritable bowel syndrome treatment market has been split into product and type. Based on product, irritable bowel syndrome treatment market has been segmented into constella/linzess, amitiza, xifaxan, viberzi, and others. The constella/linzess segment accounted for the highest market share in 2018 due to increasing acceptance of the product.
The type segment has been segmented into IBS-D and IBS-C. The IBS-C segment accounted for the highest market share in 2018 due to high prevalence of IBS-C. IBS-D has been divided into viberzi, xifaxan, and others. IBS-C has been divided into amitiza, constella/linzess, and others.
Regionally, the irritable bowel syndrome treatment market is segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa. North America will be the leading region during the forecast period. Presence of major companies, presence of modern healthcare infrastructure, and availability of novel treatment options will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are presence of skilled physicians and high healthcare expenditure. Asia Pacific will grow at rapid rate over the forecast time-frame due to launch of novel products, increasing patient awareness, growing government initiatives. The market in Latin America will grow at a substantial rate during the estimate period. The Africa and Middle Eastern region is expected to exhibit definite progression in the anticipated time-frame.
The report also includes detailed profiles of key players such as Allergan, Ironwood Pharmaceuticals, Inc., Astellas Pharma, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Synergy Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Ardelyx, Synthetic Biologics, Inc., and Bausch Health among others.
This report segments the Global Irritable Bowel Syndrome Treatment Market as follows:
Global Irritable Bowel Syndrome Treatment Market: By Product
Global Irritable Bowel Syndrome Treatment Market: By Product
Global Irritable Bowel Syndrome Treatment Market: By Region
Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/irritable-bowel-syndrome-treatment-market